Actively Recruiting

Phase 4
Age: 18Years - 85Years
All Genders
ID05487417

Effects of Minocycline on Patients With Acute Anterior Circulation Ischemic Stroke Undergoing Intravenous Thrombectomy

Led by Xijing Hospital · Updated on 2025-07-24

180

Participants Needed

1

Research Sites

13 weeks

Total Duration

On this page

Sponsors

X

Xijing Hospital

Lead Sponsor

X

Xi'an No.3 Hospital

Collaborating Sponsor

AI-Summary

What this Trial Is About

Researchers are studying the effects of minocycline, a second-generation tetracycline antibiotic, on patients with acute anterior circulation ischemic stroke who undergo mechanical thrombectomy. Minocycline is known for its ability to cross the blood-brain barrier and has shown potential neuroprotective effects in animal and clinical studies by reducing brain damage and improving neurological outcomes after stroke. This study aims to explore the safety and effectiveness of minocycline as an additional treatment alongside mechanical thrombectomy in these patients. Participants in this trial are randomly assigned to one of two groups. One group receives minocycline orally at a dose of 200 mg per day for five days starting from admission, alongside mechanical thrombectomy and standard stroke treatments. The other group receives mechanical thrombectomy and standard care without minocycline. The study monitors patients during the acute phase after stroke treatment. During the study, researchers measure changes in the volume of brain infarction from baseline to day 5 after stroke onset as the primary outcome. Secondary outcomes include neurological function improvement, functional status, and survival at three months. Other assessments include the occurrence of brain hemorrhage, length of hospital and ICU stays, and daily living activities. Participants are monitored closely throughout their hospital stay and followed up for three months to evaluate overall recovery and safety of the treatments.

CONDITIONS

Brief Title

Effects of Minocycline on Patients With Ischemic Stroke Undergoing Intravenous Thrombectomy

Who Can Participate

Age: 18Years - 85Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Patients with acute cerebral infarction of anterior circulation accompanied by large vessel occlusion
  • Age between 18 and 85 years old
  • Stroke onset time within 6 hours or up to 24 hours if suitable for mechanical thrombectomy by imaging
  • Infarct volume less than one-third of the MCA blood supply area for 6-24 hour onset; ASPECTS score 6 or higher if onset is within 6 hours
  • Preoperative NIHSS score between 6 and 30
  • Signed informed consent form
Not Eligible

You will not qualify if you...

  • Contraindications for mechanical thrombectomy
  • No revascularization therapy or TICI score less than 2b after therapy
  • Other major central nervous system diseases like brain injury, tumor, or multiple sclerosis
  • Evidence of bacterial endocarditis, aortic dissection, arteritis, or venous cerebral infarction
  • Renal or hepatic insufficiency beyond specified lab values
  • History of congestive heart failure or myocardial infarction within 6 months
  • Life-threatening or severe diseases affecting 3-month follow-up
  • Pre-existing neurological deficits or dementia
  • Infectious diseases requiring antibiotics before stroke
  • Allergy to tetracyclines or unable to take minocycline
  • Minocycline cannot be administered within 1 hour after recanalization
  • Pregnant patients
  • Participation in another clinical trial within 30 days
  • Refusal to sign informed consent form

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Your Study Journey

Screening

Duration - 2 to 4 weeks

Participants are screened for eligibility to participate in the trial.

1 visit (in-person)

Treatment

Duration - 5 days

Participants receive mechanical thrombectomy and other standard treatments for acute ischemic stroke. Those in the treatment group also take minocycline 200mg daily orally for 5 days starting on the day of admission.

Daily visits or assessments during treatment period

Follow-up

Duration - 3 months

Participants are monitored for neurological function improvement, functional outcomes, and safety up to 3 months after stroke onset.

Visits at day 7, day 30, and 3 months after onset

Trial Site Locations

Total: 1 location

1

Xijing Hospital

Xi'an, China

Actively Recruiting

Loading map...

Research Team

W

Wen Jiang, Ph.D

F

Fang Yang, Ph.D

How is the study designed?

Study Type

INTERVENTIONAL

Masking

SINGLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Similar Trials

Efficacy and Safety of Bevifibatide Citrate Injection in Pat...

Ischemic Stroke, Acute

Actively Recruiting

1 location

A Multicenter Study Based on Multi-omics Analysis to Predict...

Ischemic Stroke, Acute

Actively Recruiting

1 location

Frequently Asked Questions

Have more questions? Get in touch with our team for quick support

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

Published Research Related To This Trial

Attenuation of acute stroke injury in rat brain by minocycline promotes blood-brain barrier remodeling and alternative microglia/macrophage activation during recovery.

Yirong Yang, Victor M Salayandia, Jeffrey F Thompson...

https://pubmed.ncbi.nlm.nih.gov/25889169

Increased Plasma Matrix Metalloproteinase-9 Levels Contribute to Intracerebral Hemorrhage during Thrombolysis after Concomitant Stroke and Influenza Infection.

Sajjad Muhammad, Oliver Planz, Markus Schwaninger

https://pubmed.ncbi.nlm.nih.gov/27560521

Safety and efficacy of natalizumab in patients with acute ischaemic stroke (ACTION): a randomised, placebo-controlled, double-blind phase 2 trial.

Jacob Elkins, Roland Veltkamp, Joan Montaner...

https://pubmed.ncbi.nlm.nih.gov/28229893